此应用程序的某些内容目前无法使用。
如果这种情况持续存在,请联系我们反馈与联系
1. (WO2015188866) NOVEL COMPOUNDS
注:相关文本通过自动光符识别流程生成。凡涉及法律问题,请以 PDF 版本为准

CLAIMS

1. A compound selected from the group consisting of

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3a]pyrimidin-5-yl]-phenyl}-ethyl)-4-methoxy-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-3-hydroxy-pyridinium bromide;

1 -(2- {5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-2-methyl-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-4-hydroxymethyl-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-4-isopropyl-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-5-hydroxy-2-methyl-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-2,4-dimethyl-pyridinium bromide;

1 -(2- {5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-3,5-dimethyl-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-

phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-2-ethyl-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluorornethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-2-(2-hydroxy-ethyl)-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-4-ethyl-pyridinium bromide;

and the pharmaceutically acceptable salts thereof.

2. A compound of formula (I)" or a pharmaceutically acceptable salt thereof


CO"

wherein the group R is selected in the group consisting of

- 4-methoxy-pyridinyl;

- 3-hydroxy-pyridinyl;

- 2-methyl-pyridinyl;

- 4-hydroxymethyl-pyridinyl;

- 4-isopropyl-pyridinyl;

- 5-hydroxy-2-methyl-pyridinyl;

- 2,4-dimethyl-pyridinyl;

- 3,5-dimethyl-pyridinyl;

- 2-ethyl-pyridinyl;

- 2-(2-hydroxy-ethyl)-pyridinyl; and

- 4-ethyl-pyridinyl.

3. A pharmaceutical composition comprising a compound as claimed in claims 1 or 2 and a pharmaceutically acceptable carrier or excipient.

4. A pharmaceutical composition as claimed in claims 1 or 2 which is adapted for oral administration or administration by the pulmonary route.

5. A compound as claimed in claims 1 or 2 for the treatment of, or for use in the manufacture of a medicament for use in the treatment of, a disease or condition in which HNE is implicated.

6. A method of treatment of a disease or condition in which HNE is implicated, comprising administering to a subject suffering such disease an effective amount of a compound as claimed in claims 1 or 2.

7. A compound for use according to claims 1 or 2, or a method of treatment according to claim 5, wherein the disease or condition is chronic obstructive pulmonary disease (COPD), bronchiectasis, chronic bronchitis, lung fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, smoking-induced emphysema or cystic fibrosis.

8. A compound for use according to claims 1 or 2 or a method of treatment according to claim 6, wherein the disease or condition is asthma, rhinitis, psoriasis, atopic dermatitis, non-atopic dermatitis, Crohn's disease, ulcerative colitis, or irritable bowel disease.